OTC
0.19USD
0.00 (0.00%)
We have scored 3 news catalysts on Lyra Therapeutics, Inc. (LYRA) over the past 12 months. The biggest single-day move next to one of them came Jan 12, 2026, when LYRA closed −45.4%: “Gold Rises Sharply; Lyra Therapeutics Shares Plunge”. Coverage across the window leans negative (average ticker sentiment −0.20). Most of the impact sits in sector financials and credit spread sensitivity.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
337.2K
P/E
—
EPS
—
Beta
0.70
52W range
0.0004-6.53
Day range
0.19–0.52
Open
0.19
Prev close
0.19
Volume
5.5K
Avg volume
8.3K
Dividend
0.00
IPO
2020-05-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lyra Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LYRA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.
